Management of Hyperkalemia in Heart Failure with Spironolactone
Introduction to Hyperkalemia Management
- The American College of Cardiology and American Heart Association recommend discontinuing aldosterone receptor antagonists when potassium exceeds 5.0 mEq/L or serum creatinine exceeds 2.5 mg/dL in men or 2.0 mg/dL in women (or eGFR <30 mL/min/1.73 m²) 1
- The American College of Cardiology and American Heart Association reinforce that aldosterone antagonists should not be administered to patients with baseline serum potassium exceeding 5.0 mEq/L 2
Hyperkalemia Risk and Management
- Real-world data shows that hyperkalemia occurs in 24-36% of unselected heart failure populations on spironolactone, far higher than the 2-5% seen in clinical trials 4
- The American College of Cardiology and American Heart Association note that development of potassium levels >5.5 mEq/L should generally trigger discontinuation or dose reduction of the aldosterone receptor antagonist 1
- The European Heart Journal suggests considering loop diuretics to increase renal potassium excretion if hyperkalemia persists 4
Treatment and Monitoring
- The American College of Cardiology and American Heart Association recommend rechecking potassium and creatinine within 2-3 days after stopping spironolactone, and continuing monitoring at 7 days, then at least monthly for 3 months 1, 2
- The American College of Cardiology and American Heart Association suggest evaluating for newer potassium binders (patiromer or sodium zirconium cyclosilicate) if hyperkalemia persists and spironolactone reinitiation is desired later 4